Drug Therapy in Brugada Syndrome

Author(s): Manlio F. Marquez, Gabriel Salica, Antonio G. Hermosillo, Gustavo Pastelin, Manuel Cardenas

Journal Name: Current Drug Targets - Cardiovascular & Hematological Disorders
Continued as Cardiovascular & Hematological Disorders-Drug Targets

Volume 5 , Issue 5 , 2005


Sudden cardiac death in healthy individuals with structurally normal hearts and a characteristic morphology of the QRS complex resembling a right bundle branch block with elevation of the ST segment in V1 to V3 is known as Brugada syndrome (BrS). Although placement of an implantable cardioverter-defibrillator is considered the only effective therapy for symptomatic patients, some authors have repeatedly reported a beneficial effect of quinidine and isoproterenol in patients with BrS. Also, isolated case reports on the usefulness of cilostazol, sotalol, and mexiletine have been described. The present article reviews the mechanisms by which these drugs may act and their role in the pharmacotherapy of BrS. Other possible agents, mainly Ito blockers, are also reviewed.

Keywords: brugada syndrome, sudden cardiac death, ventricular fibrillation, arrhythmic storm, quinidine, isoproterenol, cilostazol, sotalol, mexiletine, tedisamil

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [409 - 417]
Pages: 9
DOI: 10.2174/156800605774370353
Price: $58

Article Metrics

PDF: 3